483
Ardelyx, Inc.Ardelyx, Inc. – FDA 483, Jul 24, 2023
Record Details
Ardelyx, Inc. in Fremont, CA, underwent an inspection focused on Postmarketing Adverse Drug Experience (PADE) Reporting. The inspection identified one observation related to the firm's failure to develop written procedures. Specifically, the firm lacked procedures for the surveillance of postmarketing adverse drug experiences, including those from social media outlets.
View Company Profile
ID · f6bc713b-a39b-4c43-8612-18defe062b7e
Other documents for Ardelyx, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.